genOway (Group)

https://www.genoway.com

genOway (Euronext Growth®: ALGEN; ISIN: FR0004053510) is a biotechnology society which aims to conceive and develop high value-added molecular, cellular and animal research models for biopharmaceutical, chemical, agrochemical and food industries, as well as academic research. With highly qualified scientific personnel, genOway operates in 28 countries in Europe, Asia and North America, and more than 260 research institutes and 80 biopharmaceutical companies. genOway is a market leader in terms of both size and customer portfolios. The company’s development is based on a broad and exclusive technology platform, as well as on strong intellectual property rights, combining patents and licensing agreements. Taking advantage of the global trend toward outsourcing the production of genetically modified research models, genOway has signed many commercial contracts with the leaders of the pharmaceutical industry (BMS, Janssen, Novartis, Pfizer, etc.), and with the most prestigious academic research centers, including King’s College London and the University of Manchester in England; Harvard, Caltech and the National Institutes of Health in the United States; the Pasteur Institute in France; the German National Genome Research Network and the Max Planck Institute in Germany. *

	Start	1999-03-01 established
	Industry	transgenic animal
	Industry 2	transgenic mouse
	Person	Fraichard, Alexandre (genOway 200610 CEO + Co-Founder)

	Region	Lyon
	Country	France
	Street	181 avenue Jean Jaurès
	City	69362 Lyon
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2018-09-25)

		* Document for »About Section«: genOway S.A.. (10/30/19). "Press Release: The Institut Pasteur and Cellectis Extend Exclusive License Rights by Granting genOway the Authority to Take Action against Infringement". Lyon & Paris.

		Record changed: 2024-02-12